Trials / Completed
CompletedNCT00537485
A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients
A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 180 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 30 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
To investigate superiority of SPM 962 over placebo in early Parkinson's disease patients in a multi-center, placebo-controlled, double-blind study following once-daily multiple transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg (12-week dose titration/maintenance period)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPM 962 | transdermal application, 1 time per day |
| DRUG | placebo | transdermal application, 1 time per day |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2007-10-01
- Last updated
- 2014-03-19
- Results posted
- 2014-03-19
Locations
6 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00537485. Inclusion in this directory is not an endorsement.